Copper accumulation and the effect of chelation treatment on cerebral amyloid angiopathy compared to parenchymal amyloid plaques.,Metallomics

当前位置： X-MOL 学术 › Metallomics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Copper accumulation and the effect of chelation treatment on cerebral amyloid angiopathy compared to parenchymal amyloid plaques.
Metallomics ( IF 2.9 ) Pub Date : 2020-02-27 , DOI: 10.1039/c9mt00306a
Xiayoue Zhu ₁ , Tiffany W Victor , Ashwin Ambi , Joseph K Sullivan , Joshua Hatfield , Feng Xu , Lisa M Miller , William E Van Nostrand

Affiliation

Accumulation of fibrillar amyloid β-protein (Aβ) in parenchymal plaques and in blood vessels of the brain, the latter condition known as cerebral amyloid angiopathy (CAA), are hallmark pathologies of Alzheimer's disease (AD) and related disorders. Cerebral amyloid deposits have been reported to accumulate various metals, most notably copper and zinc. Here we show that, in human AD, copper is preferentially accumulated in amyloid-containing brain blood vessels compared to parenchymal amyloid plaques. In light of this observation, we evaluated the effects of reducing copper levels in Tg2576 mice, a transgenic model of AD amyloid pathologies. The copper chelator, tetrathiomolybdate (TTM), was administered to twelve month old Tg2576 mice for a period of five months. Copper chelation treatment significantly reduced both CAA and parenchymal plaque load in Tg2576 mice. Further, copper chelation reduced parenchymal plaque copper content but had no effect on CAA copper levels in this model. These findings indicate that copper is associated with both CAA deposits and parenchymal amyloid plaques in humans, but less in Tg2576 mice. TTM only reduces copper levels in plaques in Tg2576 mice. Reducing copper levels in the brain may beneficially lower amyloid pathologies associated with AD.

中文翻译：

与实质淀粉样蛋白斑块相比，铜积累和螯合治疗对脑淀粉样蛋白血管病的影响。

纤维状淀粉样蛋白 β-蛋白 (Aβ) 在脑实质斑块和脑血管中的积累，后者称为脑淀粉样血管病 (CAA)，是阿尔茨海默病 (AD) 和相关疾病的标志性病理。据报道，大脑淀粉样蛋白沉积物会积累各种金属，最显着的是铜和锌。在这里，我们表明，在人类 AD 中，与实质淀粉样蛋白斑块相比，铜优先积聚在含淀粉样蛋白的脑血管中。根据这一观察结果，我们评估了降低 Tg2576 小鼠（一种 AD 淀粉样蛋白病变的转基因模型）中铜水平的效果。将铜螯合剂四硫代钼酸盐 (TTM) 施用于十二个月大的 Tg2576 小鼠，为期五个月。铜螯合治疗显着降低了 Tg2576 小鼠的 CAA 和实质斑块负荷。此外，铜螯合降低了实质斑块铜含量，但对该模型中的 CAA 铜水平没有影响。这些发现表明铜与人类的 CAA 沉积和实质淀粉样蛋白斑块有关，但在 Tg2576 小鼠中较少。TTM 仅降低 Tg2576 小鼠斑块中的铜水平。降低大脑中的铜水平可能有益地降低与 AD 相关的淀粉样蛋白病变。TTM 仅降低 Tg2576 小鼠斑块中的铜水平。降低大脑中的铜水平可能有益地降低与 AD 相关的淀粉样蛋白病变。TTM 仅降低 Tg2576 小鼠斑块中的铜水平。降低大脑中的铜水平可能有益地降低与 AD 相关的淀粉样蛋白病变。

更新日期：2020-02-21

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11